ALDX - Aldeyra Therapeutics, Inc.
| Previous Close | 9.49 |
| Open | 9.43 |
| Bid | 9.10 x 800 |
| Ask | 9.90 x 1100 |
| Day's Range | 9.25 - 9.55 |
| 52 Week Range | 6.20 - 16.70 |
| Volume | 129,789 |
| Avg. Volume | 739,712 |
| Market Cap | 248.272M |
| Beta (3Y Monthly) | 1.58 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.77 |
| Earnings Date | Aug 6, 2018 - Aug 10, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.57 |
- Thomson Reuters StreetEvents•7 days ago
Edited Transcript of ALDX earnings conference call or presentation 14-Nov-18 1:00pm GMT
Q3 2018 Aldeyra Therapeutics Inc Earnings Call
- Simply Wall St.•16 days ago
Should You Be Concerned About Aldeyra Therapeutics Inc’s (NASDAQ:ALDX) Historical Volatility?
If you’re interested in Aldeyra Therapeutics Inc (NASDAQ:ALDX), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could Read More...
- PR Newswire•18 days ago
Aldeyra Therapeutics to Participate at Citi's 2018 Global Healthcare Conference
LEXINGTON, Mass. , Nov. 28, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of ...
- PR Newswire•last month
Aldeyra Therapeutics Announces Third Quarter 2018 Financial Results
Reported Positive Data from Phase 2b Clinical Trial of Topical Ocular Reproxalap in Dry Eye Disease Announced Positive Top-Line Data from Investigator-Sponsored Phase 1/2 Clinical Trial of ADX-1612 in ...
- GlobeNewswire•last month
Recent Analysis Shows Freightcar America, Anworth Mortgage Asset, AMN Healthcare Services, Cenovus Energy, Dynex Capital, and Aldeyra Therapeutics Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Nov. 08, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- PR Newswire•last month
Aldeyra Therapeutics to Present at the 2018 Stifel Healthcare Conference
LEXINGTON, Mass. , Nov. 6, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of ...
- PR Newswire•last month
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third Quarter 2018 Financial Results
LEXINGTON, Mass. , Nov. 5, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of ...
- GlobeNewswire•2 months ago
Research Report Identifies Aldeyra Therapeutics, AAON, Douglas Dynamics, Insmed, Northern Oil and Gas, and SMART Global with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Oct. 16, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Insider Monkey•2 months ago
Mangrove Partners: Performance, AUM, and Holdings
Mangrove Partners is among the best performing hedge funds in previous years. It was symbolically named after a tree species that is extremely resistant, able to bear everything from storms to hurricanes. Correspondingly, Mangrove Partners aims to be tough in the financial markets. It was founded by its current president and portfolio manager, Nathaniel August, […]
- Zacks•3 months ago
Aldeyra Therapeutics (ALDX) Looks Good: Stock Adds 7.5% in Session
Aldeyra Therapeutics (ALDX) shares rose nearly 8% in the last trading session, amid huge volumes.
- PR Newswire•3 months ago
Aldeyra Therapeutics to Present at the 2018 Cantor Global Healthcare Conference
LEXINGTON, Mass. , Sept. 28, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of ...
- PR Newswire•3 months ago
Aldeyra Therapeutics, Inc. Announces Public Offering of Common Stock
LEXINGTON, Mass., Sept. 27, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced the pricing of an underwritten public offering of 5,250,000 shares of its common stock at a public offering price of $13.75 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Aldeyra, are expected to be approximately $72.2 million. In addition, Aldeyra granted the underwriters a 30-day option to purchase up to 787,500 additional shares of common stock at the public offering price, less the underwriting discounts and commissions.
- Zacks•3 months ago
Aldeyra Surges on Positive Dry Eye Study Data on Reproxalap
Aldeyra Therapeutics' (ALDX) dry eye candidate, reproxalap, achieves early onset of improvement in patients and a broad range of activity.
- Benzinga•3 months ago
The Daily Biotech Pulse: Hologic Goes Shopping, Johnson & Johnson Snaps Ties With Geron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Sept. 26) Abbott Laboratories (NYSE: ABT ) Aldeyra Therapeutics ...
- ACCESSWIRE•3 months ago
Today’s Research Reports on Stocks to Watch: Aldeyra Therapeutics and Alexion Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / September 27, 2018 / Separate positive developments sent shares of biotech stocks Aldeyra Therapeutics and Alexion Pharmaceuticals higher on Wednesday. It was encouraging phase 2b trial results from Aldeyra and acquisition news from Alexion Pharmaceuticals that had traders cheering. Aldeyra Therapeutics, Inc. shares were up nearly 35% at the close yesterday on colossal trading volume compared to usual.
- PR Newswire•3 months ago
Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
LEXINGTON, Mass., Sept. 26, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that it intends to offer and sell, subject to market and other conditions, 5,250,000 shares of its common stock in an underwritten public offering. Aldeyra also expects to grant the underwriters a 30-day option to purchase up to an additional 787,500 shares of common stock, at the public offering price, less the underwriting discounts and commissions. All of the shares in the offering are to be sold by Aldeyra, with net proceeds to be used for the continued development of Aldeyra's lead compound reproxalap and its other product candidates, as well as for debt maintenance, working capital and other general corporate purposes.
- InvestorPlace•3 months ago
Aldeyra Therapeutics Stock Skyrockets on Dry Eye Study Results
Aldeyra Therapeutics stock (NASDAQ:ALDX) was skyrocketing early in the day Wednesday as the company announced the results of its latest dry eye drug study.Source: Flickr
- Benzinga•3 months ago
The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Sept. 25) Abbott Laboratories (NYSE: ABT ) Amarin Corporation ...
- MarketWatch•3 months ago
Alderya's stock rockets after positive trial results of mesothelioma treatment
Shares of Aldeyra Therapeutics Inc. rocketed 35% toward a record high in active premarket trade Wednesday, after the biotechnology company announced positive results from a phase 1/2 trial of its treatment for pleural malignant mesothelioma. "The MESO-2 results are highly encouraging," said Dean Fennell, chief investigator of the cancer research UK Meso-2 clinical trial. "Addition of ADX-1612 to pemetrexed and either cisplatin or carboplatin achieved an overall response rate of 61%, the highest seen to date for addition of a novel agent to front-line chemotherapy." Aldeyra Chief Executive Todd Brady said he looks forward to meeting with regulatory authorities to discuss the results. The stock has run up 46% year to date through Tuesday, while the iShares Nasdaq Biotechnology ETF has rallied 13% and the S&P 500 has gained 9.1%.
- PR Newswire•3 months ago
Aldeyra Therapeutics Announces Positive Results from Phase 2b Dry Eye Disease Clinical Trial
LEXINGTON, Mass., Sept. 26, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced positive results from its Phase 2b clinical trial of topical ocular reproxalap in patients with dry eye disease. "The early onset and broad activity observed in the Phase 2b clinical trial suggests that reproxalap could be an important treatment option relative to existing therapies," commented John Sheppard, M.D., Professor of Ophthalmology, Eastern Virginia Medical School. The randomized, vehicle-controlled, parallel-group, multi-center, double-masked Phase 2b clinical trial investigated 0.1% and 0.25% concentrations of reproxalap topical ophthalmic solution versus vehicle.
- PR Newswire•3 months ago
Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Results from Phase 2b Dry Eye Disease Clinical Trial
LEXINGTON, Mass. , Sept. 25, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of ...
- PR Newswire•3 months ago
Aldeyra Therapeutics Announces Positive Mesothelioma Investigator-Sponsored Clinical Trial Results Presented at The International Association for The Study of Lung Cancer 19th World Conference on Lung Cancer
LEXINGTON, Mass., Sept. 25, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (Aldeyra) (ALDX), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced positive top-line results from the MESO-2 investigator-sponsored Phase 1/2 clinical trial of ADX-1612 (ganetespib) in patients with pleural malignant mesothelioma. "The MESO-2 results are highly encouraging. Addition of ADX-1612 to pemetrexed and either cisplatin or carboplatin achieved an overall response rate of 61%, the highest seen to date for addition of a novel agent to front-line chemotherapy" said Professor Dean Fennell MD PhD, Chief Investigator of the Cancer Research UK MESO-2 clinical trial.
- Zacks•3 months ago
Implied Volatility Surging for Aldeyra Therapeutics (ALDX) Stock Options
Aldeyra Therapeutics (ALDX) needs investors to pay close attention to the stock based on moves in the options market lately.
- PR Newswire•4 months ago
Aldeyra Therapeutics Announces Second Quarter 2018 Financial Results and Provides Corporate Update
Phase 2b Results for Topical Ocular Reproxalap in Dry Eye Disease Expected in Late Third Quarter or Early Fourth Quarter 2018 Clinical Results from Investigator-Sponsored Trial of ADX-1612 in Mesothelioma ...
